Audentes is a biotechnology company committed to the development and commercialization of innovative new treatments for people with serious, rare muscle diseases through the application of adeno-associated virus (AAV) gene therapy technology. The company consists of a focused, experienced and passionate team driven by the goal of improving the lives of patients. Audentes takes pride in strong, global relationships with the patient, research and medical communities.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/19/13 | $30,000,000 | Series A |
5AM Ventures OrbiMed Advisors Versant Ventures | undisclosed |
